Solid Biosciences (SLDB, Financial) continues to attract attention as Chardan Capital's analyst, Geulah Livshits, maintains the stock's current "Buy" rating. The decision was reported on May 19, 2025, highlighting a strategic stance on the company's future prospects despite a revised price target.
Chardan Capital adjusted its price target for Solid Biosciences (SLDB, Financial) from the previous $16.00 to $15.00. This change represents a 6.25% decrease from the prior estimate, reflecting updated assessments of the company's valuation.
Investors and market watchers will note that while the price target has been lowered, the "Buy" rating remains unchanged, suggesting confidence in the potential growth of Solid Biosciences (SLDB, Financial). The revised target price is expressed in USD currency.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Solid Biosciences Inc (SLDB, Financial) is $16.11 with a high estimate of $20.00 and a low estimate of $10.00. The average target implies an upside of 481.63% from the current price of $2.77. More detailed estimate data can be found on the Solid Biosciences Inc (SLDB) Forecast page.
Based on the consensus recommendation from 13 brokerage firms, Solid Biosciences Inc's (SLDB, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
